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Abstract
Background: Recent studies have proposed that the serine protease inhibitor E2 (SERPINE2) was
a novel susceptibility gene for chronic obstructive pulmonary disease (COPD) in Caucasians.
However, this issue still remained controversial. Additional evidences from populations with
different environments and/or genetic backgrounds, such as East Asian, would be helpful to
elucidate the issue.
Methods: In this study, five proposed causal SNPs in SERPINE2 were genotyped in 327 COPD
patients and 349 controls, all of which belonged to the Han population sampled from Southwest
China. The frequency of each SNP was compared both individually and in combination between
patients and controls. The potential relationship between these SNPs and severity of COPD was
also investigated.
Results:  Three SNPs (rs3795877, rs6747096, and rs3795879) showed complete linkage
disequilibrium (r2 = 1), and the minor allele frequencies were 13.0% and 12.9% in case and control
cohorts, respectively, with no significant difference observed (P = 0.96). We also failed to observe
any significant correlation between these SNPs and COPD severity (P = 0.67). The other two SNPs
(rs7579646 and rs840088) also presented a similar pattern. Moreover, four major haplotypes were
observed in our sample but none showed a significant difference between case and control groups
(P > 0.1).
Conclusion: Our results failed to obtain the evidence that these SNPs in SERPINE2 contributed
to the COPD susceptibility in the Han Chinese population.
Background
Chronic obstructive pulmonary disease (COPD, MIM#
606963), one of the major sources of morbidity all over
the world [1], is characterized by airflow limitation that is
not fully reversible and a chronic persistent inflammatory
process [2]. Tobacco smoking has been proven to be the
predominant environmental factor for COPD. However,
only approximately 15% of smokers develop airway
obstruction [3,4]. This phenomenon, together with the
familial clustering in patients with COPD [5], suggested
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that genetic factors might play an important role in COPD
development.
Numerous studies have demonstrated that the balance
between the serine proteases and serine protease inhibi-
tors (SERPINs) is important in maintaining the matrix
biology of the lung cells [6-8] and an imbalance between
these two factors has been a long-standing hypothesis to
explain lung destruction in emphysema during develop-
ing COPD [7]. However, in the SERPINs family, only
SERPINA1 (α1-antitrypsin) has been confirmed to be a
genetic risk factor for this disease so far. In addition, the
mutant protease inhibitor (Pi) Z homozygote of the
SERPINA1 gene, which can increase individual suscepti-
bility to COPD, is rare across worldwide populations
(0.001% – 4.5%), especially in Asians (< 0.004%), and
accountable for only 2% COPD patients [9]. All of these
observations suggested that other members of this gene
family may also be involved in the onset of COPD and
deserve further investigation.
Serine protease inhibitor E2 (SERPINE2, NM_006216) is
one member of the SERPINs family. Due to the elevated
expression of SERPINE2 in murine lung development,
and consistent correlations with COPD-related pheno-
types in human lung tissues, SERPINE2 was supposed to
be a novel candidate gene for COPD [10]. Further investi-
gation identified some SNPs in SERPINE2 that might con-
fer individual susceptibility to COPD by influencing
matrix metalloproteinase pathways [10,11]. However,
this issue was questionable since these associations have
not yet been verified [12]. To untangle this controversy
and illustrate the relationship between SERPINE2  and
COPD, additional evidence from populations with differ-
ent environments and/or genetic backgrounds is war-
ranted. Moreover, all of the above studies focused only on
Caucasians, it remains unclear whether their conclusions
also applied to East Asian populations, whose genetic
background has been proven to be strikingly different
from Caucasian.
In the present study, the five putative causal SNPs in
SERPINE2 were genotyped in a case-control population
from southwest Han Chinese and their potential correla-
tions with COPD were evaluated. Furthermore, the rela-
tionship between SERPINE2 and COPD severity was also
investigated. Our results would help to illustrate the
genetic contribution to this disease.
Methods
Study population
327 unrelated patients with COPD and 349 healthy
smokers were recruited from the First Affiliated Hospital
of Kunming Medical College (Kunming, China). All
smokers belonged to the Han nationality to minimize the
potential sampling bias due to population stratification.
COPD patients were diagnosed based on the results from
multiple examinations, including the ratio of forced expir-
atory volume in one second/forced vital capacity (FEV1/
FVC ratio < 70%), and FEV1 < 80% predicted, according to
the Global Initiative for Chronic Obstructive Lung Disease
criteria [2]. Based on the pulmonary function, the patients
were further classified into two subgroups: mild/moder-
ate COPD (FEV1 > 50% pred); and severe/very severe
COPD (FEV1 ≤ 50% pred), to evaluate whether SERPINE2
contributed to the disease severity. The healthy smokers
exhibited normal pulmonary function (FEV1/FVC > 70%
and FEV1 > 80% pred) and a smoking history ≥ 10 pack-
yrs, and were excluded from the possibility of COPD by a
Chest CT. This study was approved by our institutional
ethics committee, and informed consent was obtained
from all participants. The detailed information of patients
and healthy smokers was listed in Table 1.
Genotyping procedures
Genomic DNA was isolated from whole blood leukocytes
by the conventional phenol-chloroform method.
Five SNPs in SERPINE2  (rs3795877, rs6747096,
rs3795879, rs7579646 and rs840088) were genotyped by
PCR amplification and direct resequencing. Since three of
them, rs3795877, rs6747096 and rs3795879, showed
strong linkage disequilibrium (LD) but yielded different
results [10,12], we included all three instead of one tag
SNP for genotyping, with the attempt to investigate
whether it was also the case in our cohort. PCR was per-
formed in a 50 μL reaction mixture consisting of 250 ng
genomic DNA, 5 μL 10 × PCR Buffer (20 mM Tris-HCl pH
8.3, 500 mM KCl, 15 mM MgCl2), 2 μL dNTP mixture, 1
μL of each primer (10 μM) and 1 U Taq DNA polymerase.
Reaction conditions for PCR were as follows: 95°C for 5
minutes, 35 cycles consisting of 94°C for 1 minute,
~56°C (detailed annealing temperature for each ampli-
con shown in Additional file 1) for 1 minute, and 72°C
for 1 minute, and finally with an incubation at 72°C for 5
minutes.
Table 1: The demographic character of study subjects
Cases Controls
Subjects (n) 327 349
Male (%) 80.1 71.9
Age 71.4 ± 9.1 * 67.0 ± 9.8 #
Smoking (pack-yrs) 30.2 ± 6.7 29.2 ± 6.9
FEV1/FVC 45.3 ± 15.6 86.4 ± 5.8
FEV1 % pred 54.9 ± 18.9 94.9 ± 8.7
FEV1 > 50% pred 170 0
FEV1 ≤ 50% pred 157 0
* data available for 210 patients, # data available for 208 subjects.
Data are presented as mean ± SD.BMC Medical Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2350/10/66
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The PCR products were separated by electrophoresis on a
1.5% agarose gel, recovered by column kit (Watson Bio-
technologies Inc., China), and resequenced directly by
BigDye™ Terminator v3.1 Cycle Sequencing kit and ABI
PRISM 3730 sequencer (Applied Biosystems Inc., USA).
The known positive and negative controls were included
in the sequencing process and all samples were sequenced
on both strands. The resulting sequences were analyzed
with DNAStar software Package (DNASTAR Inc., USA).
Statistical analysis
Age, smoking history, and pulmonary function data were
displayed as mean ± SD. Hardy-Weinberg equilibrium
was tested using a goodness-of-fit χ2 test with one degree
of freedom. The frequencies of each SNP between patients
and controls, and between different disease groups (mild/
moderate vs. severe/very severe) were compared by two-
tailed Chi-square tests. All statistical tests were performed
in SPSS 13.0 (SPSS Inc., USA). Pairwise LD between each
SNP was evaluated by a maximum likelihood method to
infer phase for dual heterozygotes, and quantified as r2.
The individual haplotypes composed of the five SNPs
were estimated from genotype data using the PHASE pro-
gram (v.2.0) [13]. Odds ratios (OR) and 95% confidence
intervals (CI) were also calculated to assess the relative
disease risk. Significance was accepted when P (Probabil-
ity) value was < 0.05.
Results
The genotype and allele frequencies of the five SERPINE2
SNPs in patients with COPD and in healthy smokers were
listed in Table 2. All five SNPs were in Hardy-Weinberg
equilibrium in both case and control group (P > 0.1).
Three SNPs (rs3795877, rs6747096 and rs3795879) were
in complete LD, which was consistent with HapMap data
(CEU, CHB and JPT populations), and thus presented the
identical pattern in genotype distribution. The genotype
frequencies of these three SNPs were 1.8%, 22.5%, and
75.7% in patients while 2.0%, 21.8%, and 76.2% in con-
trols, for homozygote of minor allele, heterozygote, and
homozygote of major allele, respectively. Due to the sim-
ilar frequencies, no significant difference was observed
(Heterozygote OR 1.03, 95%CI 0.72–1.48, Homozygote
OR 0.92 95%CI 0.30–2.77, P = 0.97). Consistent with
genotype distribution, a nearly identical minor allele fre-
quency, 13.0% in cases and 12.9% in controls respec-
tively, was obtained (P  = 0.96). The other two SNPs,
rs7579646 and rs840088, showed a similar pattern to the
first three (see Table 2). Since COPD was observed mainly
in males, we excluded 64 women from the case cohort
Table 2: Genotypes and alleles distribution in patients with COPD and healthy smokers
Case (%) Control (%) OR [95% CI] P value
Allele test Genotype test HWE*
rs7579646
A 17.6 18.2 0.77 0.62 0.60
G/G 69.4 67.3 1.00
G/A 26.0 28.9 0.87 [0.62–1.23]
A/A 4.6 3.7 1.19 [0.56–2.56]
rs840088
T 43.0 43.3 0.91 0.91 0.22
C/C 33.3 33.8 1.00
C/T 47.4 45.8 1.05 [0.75–1.48]
T/T 19.3 20.3 0.96 [0.63–1.47]
rs3795877
C 13.0 12.9 0.96 0.97 0.57
T/T 75.8 76.2 1.00
T/C 22.3 21.8 1.03 [0.72–1.48]
C/C 1.8 2.0 0.92 [0.30–2.77]
rs6747096
G 13.0 12.9 0.96 0.97 0.57
A/A 75.8 76.2 1.00
A/G 22.3 21.8 1.03 [0.72–1.48]
G/G 1.8 2.0 0.92 [0.30–2.77]
rs3795879
A 13.0 12.9 0.96 0.97 0.57
G/G 75.8 76.2 1.00
G/A 22.3 21.8 1.03 [0.72–1.48]
A/A 1.8 2.0 0.92 [0.30–2.77]
SNP = Single nucleotide polymorphism, OR = Odds ratio, CI = Confidence interval.
*P-value from test for Hardy-Weinberg equilibrium in controlsBMC Medical Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2350/10/66
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and 98 women from the control population and conse-
quently only males were considered for further analysis.
The results, however, were still not significant (data not
shown).
In order to investigate whether SERPINE2 SNPs contrib-
uted to the severity of COPD, we also compared the fre-
quencies of these five SNPs in mild/moderate and severe/
very severe subgroups (shown in Table 3). The three SNPs
in complete LD (rs3795877, rs6747096 and rs3795879)
presented a similar pattern in minor allele frequency:
13.5% in the mild/moderate group while 12.4% in the
severe/very severe one respectively, suggesting that there
was no significant difference (P = 0.67). The genotype dis-
tribution of these three SNPs also failed to yield a signifi-
cant result (P = 0.86). The other two SNPs (rs7579646 and
rs840088) displayed a similar result (see Table 3). In both
total cohort and subgroup analysis, these results did not
change after adjusting for multiple significant testing by
Bonferroni correction or false discovery rate (FDR).
To further assess whether any of the SNPs influence
COPD onset, logistic regression analysis was performed in
418 subjects (210 cases and 208 controls) with full
records in age, sex, smoking history and all genotyping
data. In this logistic regression analysis, FEV1 (% pred)
that classified the case and control was regarded as the
outcome variable, while sex and smoking history were
covariates with allele count (0/1/2) for each SNP geno-
type. Our results indicated that men were more likely to
develop COPD than women, and COPD was more preva-
lent in elderly persons, which was in agreement with the
previous study [14]. However, others factors, including
the genetic variants, did not influence FEV1 (% pred) (data
not shown).
We also calculated the pairwise LD for the five SNPs. There
was complete LD among the three SNPs: rs3795877,
rs6747096 and rs3795879 (r2 = 1). The other two SNPs
(rs7579646 and rs840088) were in low LD both with the
three abovementioned ones (r2 = 0.478 and 0.133, respec-
tively) and within themselves (r2 = 0.288). In addition to
single SNP analysis, a combination analysis for these
SNPs was also performed. The result indicated that there
were four major haplotypes with a frequency above 3% in
our samples, and their frequencies varied from 7.1% to
54.6% in patients (shown in Table 4). No haplotypes were
observed to affect the OR of COPD significantly (ORs
range 0.87–1.19; P > 0.1), which was consistent with the
results of single SNP analysis.
Table 3: Distribution of genotypes and alleles in copd subgroups
mild/moderate (%) severe/very severe (%) OR [95% CI] P value
Allele test Genotype test
rs7579646
A 17.4 17.8 0.87 0.63
G/G 70.6 68.2 1.00
G/A 24.1 28.0 0.83 [0.50–1.37]
A/A 5.3 3.8 1.34 [0.46–3.87]
rs840088
T 45.0 40.8 0.27 0.26
C/C 29.4 37.6 1.00
C/T 51.2 43.3 1.51 [0.92–2.47]
T/T 19.4 19.1 1.30 [0.70–2.42]
rs3795877
C 13.5 12.4 0.67 0.86
T/T 74.7 77.1 1.00
T/C 23.5 21.0 1.15 [0.68–1.95]
C/C 1.8 1.9 0.95 [0.19–4.81]
rs6747096
G 13.5 12.4 0.67 0.86
A/A 74.7 77.1 1.00
A/G 23.5 21.0 1.15 [0.68–1.95]
G/G 1.8 1.9 0.95 [0.19–4.81]
rs3795879
A 13.5 12.4 0.67 0.86
G/G 74.7 77.1 1.00
G/A 23.5 21.0 1.15 [0.68–1.95]
A/A 1.8 1.9 0.95 [0.19–4.81]
SNP = Single nucleotide polymorphism, OR = Odds ratio, CI = Confidence interval.BMC Medical Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2350/10/66
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Discussion
Since COPD is a complex disease caused by multiple
genetic and environmental factors, it is essential to obtain
more data on different populations to elucidate the role of
the SERPINE2 in COPD. In the present study, we provided
new genotyping data of SERPINE2 SNPs in the Han Chi-
nese population, but failed to obtain any significant asso-
ciation between SNPs, including both genotype and
haplotype, and the disease phenotype. Our results were
not consistent with DeMeo's [10], but confirmed the con-
clusion of Chappell et al. [12]. Interestingly, a recent
paper from the DeMeo group also failed to replicate their
original result on these five SNPs in another population
either [11]. It was also worth mentioning that several
other SNPs, such as rs6734100, which failed to present
correlation with COPD in original study [10], showed the
most significant association in Zhu et al. [11] and
deserved further investigation.
When conflicting results among different studies of this
kind occur, common explanations include population
stratification, genetic heterogeneity, phenotypic heteroge-
neity, and statistical power. Generally, genetic heterogene-
ity is often a factor to explain this conflict [15].
Considering that the genetic background of Caucasians is
strikingly different from that of East Asians, we cannot
rule out the possibility that the conflict may just reflect the
different pathology of this disease in different ethnic pop-
ulations.
Sometimes a small sample size may bring some bias into
association studies [15]. To investigate whether our sam-
ple size was sufficient to detect genetic determinants of
minor effect, we assessed the power of our sample size by
using the genetic power calculator [16]. With the 2.0%
disease prevalence in the Kunming population [17] and α
= 0.05, for a variant with 0.1–0.4 minor allele frequency
in an additive model, our sample size provided 60%
power to detect a genetic relative risk (or OR) of 1.5, while
for a genotypic OR of 1.75, the power increased to ≥ 80%.
In addition to these, it was worth noting that some results
of statistical analyses were not interpreted decently in
DeMeo et al. [10]. Since as many as 48 SNPs were geno-
typed and investigated in that study, over two SNPs would
yield a significant result by chance given a random distri-
bution and a threshold of 0.05. To reduce any false posi-
tive effect and obtain a reasonable result, some
corrections, such as Bonferroni correction or FDR, would
be crucial, and would definitely lower the significance
level dramatically. Since the original genotyping data of
DeMeo et al. [10] was not available and thus the FDR
could not be calculated, Bonferroni correction was used,
despite the fact that this method was somewhat conserva-
tive. As a result, the original significance level, 0.05,
should be divided by 16, since at least 16 independent LD
blocks exist among their 48 SNPs according to HapMap
data in the Caucasian population (LD pattern not shown)
and consequently, a much stricter one, 0.003, should be
applied for assessing significance. Under this circum-
stance, most P values in DeMeo et al.' result would be
beyond this threshold and thus these SNPs should not be
considered to be positive, which was in agreement with
Chappell et al. [12] and our results.
Another concern is about the potential mechanism how
these SNPs in SERPINE2 could play a role in COPD sus-
ceptibility. Since these five SNPs are located in the first
three introns and over-expression of SERPINE2 was sup-
posed to be correlated with COPD [10], it was reasonable
to hypothesize that these SNPs might alter the SERPINE2
expression in tissues, given these five SNPs really corre-
lated with COPD susceptibility. To test this hypothesis, we
retrieved the gene expression data of SERPINE2 from Hap-
Map lymphoblastoid cell line [18] and HapMap genotype
data [19], and performed a linear regression analysis on
these five SNPs in four HapMap populations. The three
SNPs in strong LD, rs3795877, rs6747096 and
rs3795879, did not present correlation with gene expres-
sion, except in the JPT population (r2 = 0.32, P = 0.0012).
Similarly, the remaining two SNPs (rs7579646 and
rs840088) also failed to show any correlation in all four
HapMap populations, except for rs840088 in the CHB
population (r2 = 0.15, P = 0.027). Considering that this
relationship was observed randomly with two SNPs in
two populations and that expression data was only avail-
Table 4: The distribution of SERPINE2 haplotypes in COPD and control groups
Haplotype * Cases (%) # Controls (%) # OR [95%CI] & P value
G C T A G 356 (54.4) 395 (56.5) 0.95 [0.77–1.19] 0.67
G T T A G 166 (25.4) 170 (24.3) 1.08 [0.84–1.39] 0.54
A T C G A 68 (10.4) 84 (12.0) 0.87 [0.62–1.22] 0.42
A T T A G 47 (7.2) 43 (6.2) 1.19 [0.78–1.82] 0.43
others 17 (2.6) 6 (1.0)
total 654 (100.0) 698 (100.0)
OR = Odds ratio, CI = Confidence interval
*Composed of five SNPs: rs7579646, rs840088, rs3795877, rs6749096, and rs3795879; # Data are presented as number of chromosome (%); &OR 
value just for the major haplotypes (haplotype frequency > 3%).BMC Medical Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2350/10/66
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able for the lymphoblastoid cell line, which represents
only one tissue type, it was far from drawing any conclu-
sion on whether these SNPs could regulate the expression
of SERPINE2. More studies on gene expression, especially
expression in lung cells or a cell line with lung derivation,
are necessary to clarify this issue.
Conclusion
In summary, our study was the first report to investigate
the association between SERPINE2 SNPs and COPD in an
East Asian population. The negative results we obtained,
in combination with the available evidence in the litera-
ture, suggest that it is still far from reaching a consensus
and more studies should be surveyed.
Abbreviations
CI: Confidence interval; COPD: Chronic obstructive pul-
monary disease; FDR: False discovery rate; LD: Linkage
disequilibrium; OR: Odds ratio; Pi: Protease inhibitor;
SERPINE2: Serine protease inhibitorE2; SERPINs: Serine
protease inhibitors; SNP: Single nucleotide polymor-
phism.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
LZ contributed to the design of this study, carried out the
molecular genetic studies, and drafted the manuscript.
WPF and LMD undertook the data collection and contrib-
uted to the editing of the manuscript. CS assisted with the
statistical analysis and the manuscript composing. YPZ
contributed to the conception and the design of the study
and critically revised the manuscript. All authors read and
approved the final manuscript.
Additional material
Acknowledgements
We appreciated Dr. Qing-Peng Kong and Liang Xie's comments. We also 
thank Ms. Catherine Southard and Ellen Leffler for going through the man-
uscript. The work was supported by grants from National Natural Science 
Foundation of China and the Science and Technology Committee of Yun-
nan Province.
References
1. Ezzati M, Lopez AD: Estimates of global mortality attributable
to smoking in 2000.  Lancet 2003, 362:847-852.
2. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: Global
strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease. NHLBI/WHO Glo-
bal Initiative for Chronic Obstructive Lung Disease (GOLD)
Workshop summary.  Am J Respir Crit Care Med 2001,
163:1256-1276.
3. Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L: Defini-
tion, epidemiology and natural history of COPD.  Eur Respir J
2007, 30:993-1013.
4. Vestbo J, Hogg JC: Convergence of the epidemiology and
pathology of COPD.  Thorax 2006, 61:86-88.
5. Givelber RJ, Couropmitree NN, Gottlieb DJ, Evans JC, Levy D, Myers
RH, O'Connor GT: Segregation analysis of pulmonary function
among families in the Framingham Study.  Am J Respir Crit Care
Med 1998, 157:1445-1451.
6. Joos L, Pare PD, Sandford AJ: Genetic risk factors of chronic
obstructive pulmonary disease.  Swiss Med Wkly 2002,
132:27-37.
7. Barnes PJ, Shapiro SD, Pauwels RA: Chronic obstructive pulmo-
nary disease: molecular and cellular mechanisms.  Eur Respir J
2003, 22:672-688.
8. Abboud RT, Vimalanathan S: Pathogenesis of COPD. Part I. The
role of protease-antiprotease imbalance in emphysema.  Int J
Tuberc Lung Dis 2008, 12:361-367.
9. de Serres FJ, Blanco I, Fernandez-Bustillo E: PI S and PI Z alpha-1
antitrypsin deficiency worldwide. A review of existing
genetic epidemiological data.  Monaldi Arch Chest Dis 2007,
67:184-208.
10. Demeo DL, Mariani TJ, Lange C, Srisuma S, Litonjua AA, Celedon JC,
Lake SL, Reilly JJ, Chapman HA, Mecham BH, et al.: The SERPINE2
gene is associated with chronic obstructive pulmonary dis-
ease.  Am J Hum Genet 2006, 78:253-264.
11. Zhu G, Warren L, Aponte J, Gulsvik A, Bakke P, Anderson WH,
Lomas DA, Silverman EK, Pillai SG: The SERPINE2 gene is asso-
ciated with chronic obstructive pulmonary disease in two
large populations.  Am J Respir Crit Care Med 2007, 176:167-173.
12. Chappell S, Daly L, Morgan K, Baranes TG, Roca J, Rabinovich R, Mil-
lar A, Donnelly SC, Keatings V, MacNee W, et al.: The SERPINE2
gene and chronic obstructive pulmonary disease.  Am J Hum
Genet 2006, 79:184-186.
13. Stephens M, Scheet P: Accounting for decay of linkage disequi-
librium in haplotype inference and missing-data imputation.
Am J Hum Genet 2005, 76:449-462.
14. Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Ni D,
Zhou Y, Liu S, et al.: Prevalence of chronic obstructive pulmo-
nary disease in China: a large, population-based survey.  Am J
Respir Crit Care Med 2007, 176:753-760.
15. Hersh CP, Demeo DL, Lange C, Litonjua AA, Reilly JJ, Kwiatkowski
D, Laird N, Sylvia JS, Sparrow D, Speizer FE, et al.: Attempted rep-
lication of reported chronic obstructive pulmonary disease
candidate gene associations.  Am J Respir Cell Mol Biol 2005,
33:71-78.
16. Purcell S, Cherny SS, Sham PC: Genetic Power Calculator:
design of linkage and association genetic mapping studies of
complex traits.  Bioinformatics 2003, 19:149-150.
17. Qiu J, Zhang MR, Gong HQ, Yan ZM, Li YT, Yang S: An analysis on
Epidemiological Status and risk factors of COPD in Kunming
Plateau District.  Practical Preventive Medicine 2005, 12:52-53. (Chi-
nese)
18. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N,
Redon R, Bird CP, de Grassi A, Lee C, et al.: Relative impact of
nucleotide and copy number variation on gene expression
phenotypes.  Science 2007, 315:848-853.
19. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA,
Belmont JW, Boudreau A, Hardenbol P, Leal SM, et al.: A second
generation human haplotype map of over 3.1 million SNPs.
Nature 2007, 449:851-861.
Pre-publication history





online supplementary material-final. Supplemental material
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-10-66-S1.doc]